University of Zurich spin-off founded in 2021, building on roughly three decades of in-human psychedelic research from the Psychiatric University Clinic Zurich and ETH Zurich. The company develops rapid-acting, sustainable drug candidates for affective disorders (anxiety, depression, trauma, addiction), sleep and neurodegenerative diseases, and emerged from stealth in August 2025 having raised over CHF 22 million in equity and grants.
Reconnect Labs News 3 articles
- Reunion to present full RECONNECT Phase 2 data for luvesilocin in postpartum depression
- Reunion's RE104 hits primary endpoint in Phase 2 RECONNECT postpartum-depression trial
- Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression